---
document_datetime: 2025-04-24 16:18:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prevenar-13-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: prevenar-13-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0076937
conversion_datetime: 2025-12-20 18:20:49.185067
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Prevenar 13

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 24/04/2025                          |                                             | SmPC, Annex                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000254585   | II and PL   |
|---------------------|-------------|

<div style=\"page-break-after: always\"></div>

|                                       | substance and the currently registered master cell bank storage site Pfizer Ireland Pharmaceuticals, Grange Castle. Â· Type IA (A.5(b)) - Change in the legal entity name and address of the currently registered manufacturer of finished product, Pfizer Ireland Pharmaceuticals, Grange Castle. In addition, the MAH took the opportunity to align the PI to the latest QRD template 10.4 and to update the contact details of the Irish local representative.   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000254759 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                               | 25/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|